Inventor · disambiguated record
Stuart Milstein
Also filed as: MILSTEIN STUART
91 granted patents·47 pending applications·623 citations·filing 2009–2025
99Inventor score
Files withALNYLAM PHARMACEUTICALS INC92ARROWHEAD PHARMACEUTICALS INC11ARROWHEAD RES CORP5KORRO BIO INC4NOVARTIS AG4
Top patents by PatentIndex Score
138 records- 0199US11525138B2Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2022·Granted Dec 13, 2022·7 cites·28 claims
- 0299US11130953B2Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Sep 28, 2021·8 cites·30 claims
- 0398US11866709B2Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Jan 9, 2024·3 cites·29 claims
- 0498US11840692B2Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Dec 12, 2023·3 cites·29 claims
- 0598US11834662B2Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Dec 5, 2023·3 cites·29 claims
- 0698US11332743B2Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2020·Granted May 17, 2022·6 cites·26 claims
- 0798US11306315B2Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Apr 19, 2022·6 cites·20 claims
- 0898US11306314B2Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Apr 19, 2022·6 cites·20 claims
- 0998US11306316B2Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Apr 19, 2022·6 cites·20 claims
- 1098US10612024B2Modified double-stranded RNA agentsALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted Apr 7, 2020·15 cites·35 claims
- 1198US10612027B2Modified double-stranded RNA agentsALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted Apr 7, 2020·26 cites·25 claims
- 1298US10233448B2Modified double-stranded RNA agentsALNYLAM PHARMACEUTICALS INC·Filed 2015·Granted Mar 19, 2019·37 cites·40 claims
- 1398US9771591B2Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2016·Granted Sep 26, 2017·22 cites·34 claims
- 1498US9322018B2Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2013·Granted Apr 26, 2016·36 cites·41 claims
- 1598US8168775B2Compositions and methods for inhibiting expression of transthyretinSAH DINAH WEN-YEE·Filed 2009·Granted May 1, 2012·84 cites·23 claims
- 1697US11034958B2Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2020·Granted Jun 15, 2021·7 cites·17 claims
- 1797US10557139B2Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted Feb 11, 2020·15 cites·20 claims
- 1897US10550390B2Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted Feb 4, 2020·15 cites·20 claims
- 1997US10337010B2Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2017·Granted Jul 2, 2019·17 cites·31 claims
- 2096US11504391B1Modified RNA agents with reduced off-target effectALNYLAM PHARMACEUTICALS INC·Filed 2017·Granted Nov 22, 2022·18 cites·42 claims
- 2196US11401517B2Modified double-stranded RNA agentsALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted Aug 2, 2022·6 cites·24 claims
- 2296US10934545B2Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted Mar 2, 2021·6 cites·25 claims
- 2396US9127274B2Serpinc1 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS·Filed 2013·Granted Sep 8, 2015·51 cites·62 claims
- 2496US8273869B2Lipid formulated dsRNA targeting the PCSK9 geneFITZGERALD KEVIN·Filed 2010·Granted Sep 25, 2012·17 cites·27 claims
- 2595US11180757B117β-hydroxysteroid dehydrogenase type 13 (HSD17B13) iRNA compositions and methods of use thereofREGENERON PHARMA·Filed 2021·Granted Nov 23, 2021·3 cites·30 claims
- 2695US8741866B2Compositions and methods for inhibiting expression of transthyretinSAH DINAH WEN-YEE·Filed 2012·Granted Jun 3, 2014·29 cites·30 claims
- 2795US8598139B2Lipid formulated dsRNA targeting the PCSK9 geneFITZGERALD KEVIN·Filed 2012·Granted Dec 3, 2013·15 cites·26 claims
- 2894US12385044B2Modified double-stranded RNA agentsALNYLAM PHARMACEUTICALS INC·Filed 2024·Granted Aug 12, 2025·0 cites·30 claims
- 2994US11419942B2Angiotensinogen (AGT) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2020·Granted Aug 23, 2022·2 cites·55 claims
- 3094US10995336B2Serpina1 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted May 4, 2021·8 cites·41 claims
- 3194US10238749B2Angiotensinogen (AGT) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2015·Granted Mar 26, 2019·12 cites·44 claims
- 3294US9234196B2Compositions and methods for inhibiting expression of transthyretinALNYLAM PHARMACEUTICALS INC·Filed 2014·Granted Jan 12, 2016·18 cites·37 claims
- 3393US12385043B2Modified double-stranded RNA agentsALNYLAM PHARMACEUTICALS INC·Filed 2024·Granted Aug 12, 2025·0 cites·35 claims
- 3492US12467051B2Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2023·Granted Nov 11, 2025·0 cites·13 claims
- 3592US10814007B2Angiotensinogen (AGT) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted Oct 27, 2020·3 cites·15 claims
- 3691US11492623B2Hepatitis B virus (HBV) dsRNA agent compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted Nov 8, 2022·4 cites·36 claims
- 3791US10829763B2TMPRSS6 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted Nov 10, 2020·4 cites·17 claims
- 3891US10240152B2Compositions and methods for inhibiting expression of transthyretinALNYLAM PHARMACEUTICALS INC·Filed 2016·Granted Mar 26, 2019·6 cites·53 claims
- 3991US9376680B2Serpinc1 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2015·Granted Jun 28, 2016·7 cites·55 claims
- 4091US9228188B2Compositions and method for inhibiting hepcidin antimicrobial peptide (HAMP) or HAMP-related gene expressionBETTENCOURT BRIAN·Filed 2012·Granted Jan 5, 2016·8 cites·22 claims
- 4190US10513703B2Hepatitis B virus (HBV) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2017·Granted Dec 24, 2019·6 cites·24 claims
- 4290US9725718B2Compositions and methods for inhibition of expression of protein C (PROC) genesALNYLAM PHARMACEUTICALS INC·Filed 2015·Granted Aug 8, 2017·3 cites·33 claims
- 4389US11408001B1Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Aug 9, 2022·1 cites·29 claims
- 4489US11142766B2Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted Oct 12, 2021·4 cites·21 claims
- 4589US11060091B2Hepatitis B virus (HBV) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted Jul 13, 2021·2 cites·45 claims
- 4689US10407679B2Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2017·Granted Sep 10, 2019·5 cites·43 claims
- 4789US2025064943A1ANGIOTENSINOGEN (AGT) iRNA COMPOSITIONS AND METHODS OF USE THEREOFALNYLAM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 4888US12168767B2Modified double-stranded RNA agentsALNYLAM PHARMACEUTICALS INC·Filed 2022·Granted Dec 17, 2024·0 cites·25 claims
- 4988US11725207B2Serpina1 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Aug 15, 2023·1 cites·123 claims
- 5088US10246713B2TMPRSS6 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2017·Granted Apr 2, 2019·6 cites·14 claims
Showing the top 50 of 138 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Stuart Milstein files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →